Stocktwits on MSN
Regenxbio stock still has over 300% upside despite FDA pushback on Hunter syndrome drug: Clear Street
Clear Street kept a 'Buy' rating, cut its price target to $45 from $50, and said its core thesis remains intact. ・The FDA ...
REGENXBIO Inc. today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding its Biologics License Application (BLA) for RGX-121 (clemidsogene ...
A new study, recently published in the journal Nature Communications, is leading to a new understanding of how immune cells ...
In this nationwide cohort study, trans Australians experienced substantially elevated mortality risk. Tailored policy responses are needed to address premature mortality in trans populations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results